170 related articles for article (PubMed ID: 3090987)
1. Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer.
Alagaratnam TT; Wong J
Aust N Z J Surg; 1986 Jan; 56(1):39-41. PubMed ID: 3090987
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.
Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Askergren J; Friberg S
Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):629-39. PubMed ID: 2493433
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial.
Buzdar AU; Blumenschein GR; Smith TL; Powell KC; Hortobagyi GN; Yap HY; Schell FC; Barnes BC; Ames FC; Martin RG
Cancer; 1984 Feb; 53(3):384-9. PubMed ID: 6362814
[TBL] [Abstract][Full Text] [Related]
5. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy in primary breast cancer.
Wolmark N; Fisher B
Surg Clin North Am; 1985 Feb; 65(1):161-80. PubMed ID: 3887616
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.
Ingle JN; Everson LK; Wieand HS; Martin JK; Votava HJ; Wold LE; Krook JE; Cullinan SA; Paulsen JK; Twito DI
J Clin Oncol; 1988 Sep; 6(9):1388-96. PubMed ID: 3047333
[TBL] [Abstract][Full Text] [Related]
8. The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial.
Saarto T; Blomqvist C; Tiusanen K; Gröhn P; Rissanen P; Elomaa I
Eur J Surg Oncol; 1995 Apr; 21(2):146-50. PubMed ID: 7720887
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
10. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
[TBL] [Abstract][Full Text] [Related]
11. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.
Rutqvist LE; Cedermark B; Fornander T; Glas U; Johansson H; Nordenskjöld B; Rotstein S; Skoog L; Somell A; Theve T
J Clin Oncol; 1989 Oct; 7(10):1474-84. PubMed ID: 2674335
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy combined with tamoxifen in postmenopausal patients with stage II breast cancer.
Zielinski CC; Kubista E; Salzer H; Sevelda P; Langer M; Staffen A; Spona J; Aiginger P
Lancet; 1986 Nov; 2(8516):1164. PubMed ID: 2877314
[No Abstract] [Full Text] [Related]
14. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
Ingle JN; Everson LK; Wieand HS; Cullinan SA; Wold LE; Hagen JB; Martin JK; Krook JE; Fitzgibbons RG; Foley JF
Cancer; 1989 Apr; 63(7):1257-64. PubMed ID: 2646004
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
J Clin Oncol; 1986 Feb; 4(2):186-93. PubMed ID: 2868074
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil compared to chemotherapy plus hormonal therapy with tamoxifen in the treatment of advanced breast cancer: an interim analysis.
Perry MC; Kardinal CG; Weinberg V; Ginsberg SJ; Hughes A; Wood W
J Steroid Biochem; 1985 Dec; 23(6B):1135-40. PubMed ID: 3912618
[TBL] [Abstract][Full Text] [Related]
17. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
18. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
Blomqvist C; Tiusanen K; Elomaa I; Rissanen P; Hietanen T; Heinonen E; Gröhn P
Br J Cancer; 1992 Dec; 66(6):1171-6. PubMed ID: 1457360
[TBL] [Abstract][Full Text] [Related]
19. Early experiences of breast-conservation treatment combined with tamoxifen and CAF chemotherapy for breast cancer of stages I and II.
Ogawa Y; Nishioka A; Inomata T; Hamada N; Terashima M; Yoshida S; Tanaka Y; Ogoshi S; Araki K; Kumon M
Radiat Med; 1994; 12(1):29-35. PubMed ID: 8016401
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.
Br J Cancer; 1988 Jun; 57(6):604-7. PubMed ID: 2900646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
